A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis

Inclusion criteria

• The age of 18~75 years old at the time of signing the informed consent form (including the values at both ends), gender is not limited；
• Previous atopic dermatitis, (1) participation in a complete main study; or (2) subjects who prematurely terminate primary study therapy for reasons other than SHR-1819 injection are required to complete a last safety follow-up or withdrawal from the visit, and the investigator assesses that the influencing factor has been eliminated/no longer affects the participant's participation in the extended study. Participants were required to meet the main study inclusion criteria for the main study；
• Be able to apply a topical emollient (moisturizer) continuously for at least 7 consecutive days before the first dose and continue to use it for the duration of the study;
• Be able to sign informed consent forms, understand and agree to follow the requirements of the study and the trial process.

Exclusion criteria

• Pregnant or lactating women；
• Female subjects of childbearing potential and male subjects whose partners are women of childbearing age have a plan to donate sperm/eggs from the signing of the informed consent form until 3 months after the last dose of the trial drug, or refuse to comply with the relevant contraceptive requirements;
• A history of alcohol abuse or illicit drug abuse within 6 months prior to screening;
• Hypersensitivity to the study drug or any ingredient in the study drug；
• Diagnosed within 6 months prior to screening or judged by the investigator to have a suspected immunosuppressive disease;
• Oral or parenteral systemic antimicrobials are used within 2 weeks before the first dose；
• Suspected or confirmed active tuberculosis (TB);
• Have malignancy or history of malignancy prior to screening；
• Major surgery was performed within 3 months prior to screening, or major surgery was planned during the study；
• There are currently significant abnormal laboratory test results, severe concomitant diseases, and other circumstances that the investigator considers inappropriate to participate in this trial;
• There were treatment-related adverse events leading to discontinuation of treatment and study drug-related SAEs in the main study, and the investigator or sponsor medical department considered that continuing to participate in extended therapy would pose an unacceptable safety risk to participants.